Nanobiotix Competitors

Cullinan Management (NASDAQ:CGEM) and Nanobiotix (NASDAQ:NBTX) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, analyst recommendations, valuation and profitability.

Analyst Ratings

This is a summary of current ratings and price targets for Cullinan Management and Nanobiotix, as provided by MarketBeat.

Cullinan Management presently has a consensus price target of $48.00, indicating a potential downside of 7.82%. Given Cullinan Management's higher probable upside, analysts plainly believe Cullinan Management is more favorable than Nanobiotix.

Earnings and Valuation

This table compares Cullinan Management and Nanobiotix's gross revenue, earnings per share (EPS) and valuation.

Profitability

This table compares Cullinan Management and Nanobiotix's net margins, return on equity and return on assets.

Summary

Cullinan Management beats Nanobiotix on 2 of the 3 factors compared between the two stocks.

Nanobiotix (NASDAQ:NBTX) and Silverback Therapeutics (NASDAQ:SBTX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, profitability, analyst recommendations and valuation.

Analyst Ratings

This is a breakdown of current recommendations for Nanobiotix and Silverback Therapeutics, as provided by MarketBeat.com.

Silverback Therapeutics has a consensus target price of $46.25, indicating a potential downside of 12.97%. Given Silverback Therapeutics' higher probable upside, analysts plainly believe Silverback Therapeutics is more favorable than Nanobiotix.

Earnings and Valuation

This table compares Nanobiotix and Silverback Therapeutics' gross revenue, earnings per share and valuation.

Profitability

This table compares Nanobiotix and Silverback Therapeutics' net margins, return on equity and return on assets.

Summary

Silverback Therapeutics beats Nanobiotix on 2 of the 2 factors compared between the two stocks.

Nanobiotix (NASDAQ:NBTX) and Vor Biopharma (NYSE:VOR) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, profitability, analyst recommendations and valuation.

Analyst Ratings

This is a breakdown of current recommendations for Nanobiotix and Vor Biopharma, as provided by MarketBeat.com.

Given Vor Biopharma's higher probable upside, analysts plainly believe Vor Biopharma is more favorable than Nanobiotix.

Earnings and Valuation

This table compares Nanobiotix and Vor Biopharma's gross revenue, earnings per share and valuation.

Profitability

This table compares Nanobiotix and Vor Biopharma's net margins, return on equity and return on assets.

Summary

Nanobiotix beats Vor Biopharma on 2 of the 3 factors compared between the two stocks.

Nanobiotix (NASDAQ:NBTX) and BioAtla (NASDAQ:BCAB) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, profitability, analyst recommendations and valuation.

Analyst Ratings

This is a breakdown of current recommendations for Nanobiotix and BioAtla, as provided by MarketBeat.com.

BioAtla has a consensus target price of $48.00, indicating a potential downside of 7.01%. Given BioAtla's higher probable upside, analysts plainly believe BioAtla is more favorable than Nanobiotix.

Earnings and Valuation

This table compares Nanobiotix and BioAtla's gross revenue, earnings per share and valuation.

Profitability

This table compares Nanobiotix and BioAtla's net margins, return on equity and return on assets.

Summary

BioAtla beats Nanobiotix on 2 of the 2 factors compared between the two stocks.

Nanobiotix (NASDAQ:NBTX) and Gracell Biotechnologies (NASDAQ:GRCL) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, profitability, analyst recommendations and valuation.

Analyst Ratings

This is a breakdown of current recommendations for Nanobiotix and Gracell Biotechnologies, as provided by MarketBeat.com.

Gracell Biotechnologies has a consensus target price of $34.50, indicating a potential upside of 44.17%. Given Gracell Biotechnologies' higher probable upside, analysts plainly believe Gracell Biotechnologies is more favorable than Nanobiotix.

Earnings and Valuation

This table compares Nanobiotix and Gracell Biotechnologies' gross revenue, earnings per share and valuation.

Profitability

This table compares Nanobiotix and Gracell Biotechnologies' net margins, return on equity and return on assets.

Summary

Gracell Biotechnologies beats Nanobiotix on 2 of the 2 factors compared between the two stocks.

Nanobiotix (NASDAQ:NBTX) and iTeos Therapeutics (NASDAQ:ITOS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, profitability, analyst recommendations and valuation.

Earnings and Valuation

This table compares Nanobiotix and iTeos Therapeutics' gross revenue, earnings per share and valuation.

Institutional & Insider Ownership

71.1% of iTeos Therapeutics shares are held by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Nanobiotix and iTeos Therapeutics' net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current recommendations for Nanobiotix and iTeos Therapeutics, as provided by MarketBeat.com.

iTeos Therapeutics has a consensus target price of $43.40, indicating a potential downside of 1.52%. Given iTeos Therapeutics' higher probable upside, analysts plainly believe iTeos Therapeutics is more favorable than Nanobiotix.

Summary

iTeos Therapeutics beats Nanobiotix on 3 of the 3 factors compared between the two stocks.